X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Grifols Misterium® Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation

Yuvraj_pawp by Yuvraj_pawp
4th December 2017
in Americas, Facilities & Operation

Grifols , a leading global producer of plasma-derived medicines and provider of sterile compounding-related technologies and services for hospitals, clinics, and compounding centers, has reached an exclusive agreement with airinspace to distribute mobile air decontamination systems and protective environment solutions for healthcare settings. Together with Grifols Misterium cleanroom solutions and operational consulting services, the distributorship with airinspace offers customers a more complete solution for mobile cleanroom technology.

Cleanrooms require strict control of environmental pollutants and must be designed and operated in compliance with relevant industry guidelines and regulations to ensure the safe preparation of compounded medications. To comply with United States Pharmacopeia (USP) Chapters <797> and <800>, many hospitals realize that changes or renovations to their current compounding environments are necessary. Aging infrastructure, deteriorating materials, uncontrolled air streams, improper filtration, and contaminated systems can compromise the environment by introducing opportunities for cross contamination, poor cleanability, and critical leaks.

“A fully compliant compounding pharmacy program starts with an adequate environmental analysis and the proper design and construction of primary engineering controls,” said Juan Miguel Cana, General Manager for North America Sales of Grifols Hospital Division. “Designing and building a cleanroom can be challenging on many levels. Continued operation is essential, but construction is a dirty job, and cleanroom environments must be protected and continuously monitored. Together, Grifols and airinspace help healthcare institutions complete this transition to USP compliance with our robust portfolio of cleanroom solutions.”

The airinspace PLASMAIR® air decontamination unit with HEPA-MD® offers unique and proprietary technology, which is validated to destroy a full spectrum of airborne microorganisms. The technologies augment the effectiveness of existing cleanrooms and segregated compounding areas, as well as serve as air quality control mechanisms in temporary cleanrooms during pharmacy renovations.

The airinspace HPVPA disinfection system diffuses a cold hydrogen peroxide and peracetic acid solution to destroy bacteria, spores, fungi and yeasts, viruses and mycobacteria, including Myobacterium tuberculosis.

Previous Post

Merck to present new and updated data of Keytruda to treat breast cancers at 2017 SABC symposium

Next Post

Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab in X-Linked Hypophosphatemia

Related Posts

Cellbox Solutions Establishes Subsidiary in the USA
Americas

Cellbox Solutions Establishes Subsidiary in the USA

24th September 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Americas

US Allows Johnson & Johnson Covid Vaccination To Resume

26th April 2021
New Concept Allows Physical Partnering Event
Facilities & Operation

New Concept Allows Physical Partnering Event

11th September 2020
POINT Biopharma to Launch First US Manufacturing Facility in Indiana
Americas

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

5th June 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
Americas

AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand

5th May 2020
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Next Post

Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab in X-Linked Hypophosphatemia

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In